Karyopharm Therapeutics (KPTI) Wild Ride Occurring as M&A Speculation Proved Wrong Amid Executive Departure - RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Morgan Stanley Reiterates Equalweight Rating on Karyopharm Therapeutics (KPTI), 'lack of potential takeout news likely to disappoint'
February 22, 2022 10:33 AM ESTMorgan Stanley analyst Michael Ulz reiterated an Equalweight rating and $10.00 price target on Karyopharm Therapeutics (NASDAQ: KPTI).
The analyst comments "CMO departure surprising, but lack of potential takeout news likely to disappoint. This morning, Karyopharm announced several changes to the clinical leadership team. Most notable, Jatin Shah, EVP and CMO for the past 5 years, is leaving to pursue other opportunities... More
Pre-Open Stock Movers 02/22: (MTOR) (VEV) (HMHC) Higher; (FIXX) (KPTI) (YNDX) Lower (more...)
February 22, 2022 9:20 AM ESTPre-Open Stock Movers:
Meritor, Inc. (NYSE: MTOR) 44.5% HIGHER; Cummins Inc. (NYSE:... More
Karyopharm Therapeutics (KPTI) CMO has stepped down to pursue other professional opportunities
February 22, 2022 7:12 AM EST(Updated - February 22, 2022 7:23 AM EST)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced changes to its clinical leadership team, including the appointment of Patricia Judson, M.D., as Senior Vice President of Medical Strategy and Stuart Poulton as Senior Vice President of Strategy and Portfolio Management. In addition, Jatin Shah, M.D. Executive Vice President and Chief Medical Officer has stepped down to pursue other professional opportunities, but will continue to serve Karyopharm in an advisory capacity.
"As accomplished leaders with proven track... More
Karyopharm Therapeutics (KPTI) CEO Cancels Leerink Conf On Scheduling Difficulties - Bloomberg
February 18, 2022 10:15 AM ESTKaryopharm Therapeutics (NASDAQ: KPTI) CEO Cancels Leerink Conf On Scheduling Difficulties - Bloomberg, Citing Email
... MoreUPDATE: Karyopharm Therapeutics (KPTI) shares gain 13% in early trading, bucking market weakness
February 18, 2022 9:37 AM EST(Updated - February 18, 2022 9:41 AM EST)
Karyopharm Therapeutics (NASDAQ: KPTI) shares gain 13% in early trading, bucking market weakness.
gains tied to news the company canceled from today's fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference. This was said... More